GSK 4Q Sales and Earnings Rose, Driven by Specialty Medicines, Vaccines
GSK PLC posted rising earnings and sales for the fourth quarter, which the company said were boosted by its specialty medicines and vaccines businesses. The British pharma major reported net profit of 1.50 billion pounds ($1.85 billion) in the fourth quarter, up from GBP749 million for the same quarter of 2021, on sales that grew to GBP7.33 billion from GBP7.08 billion. Operating profit increased to GBP1.87 billion from GBP492 million in the fourth quarter of 2021, reflecting fair-value gains on investments, milestone income from disposals and lower remeasurement charges for contingent consideration liabilities, GSK said. After-tax profit also increased, rising to GBP1.62 billion from GBP930 million the previous year.